VistaGen Therapeutics (VTGN)
(Delayed Data from NSDQ)
$4.75 USD
+0.05 (1.06%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $4.77 +0.02 (0.42%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
Income Statements
Fiscal Year end for VistaGen Therapeutics, Inc falls in the month of March .
All items in Millions except EPS data.
3/31/24 | 3/31/23 | 3/31/22 | 3/31/21 | 3/31/20 | |
---|---|---|---|---|---|
Sales | NA | 0 | 1 | 1 | 0 |
Cost Of Goods | NA | 0 | 0 | 0 | 0 |
Gross Profit | NA | 0 | 1 | 1 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 0 | 59 | 49 | 19 | 21 |
Income After Depreciation & Amortization | 0 | -59 | -48 | -18 | -21 |
Non-Operating Income | NA | 0 | 0 | 0 | 0 |
Interest Expense | NA | 0 | 0 | 0 | 0 |
Pretax Income | NA | -59 | -48 | -18 | -21 |
Income Taxes | NA | 0 | 0 | 0 | 0 |
Minority Interest | NA | 0 | 0 | 0 | 0 |
Investment Gains/Losses | NA | 0 | 0 | 0 | 0 |
Other Income/Charges | NA | 0 | 0 | 0 | 0 |
Income From Cont. Operations | NA | -59 | -48 | -18 | -21 |
Extras & Discontinued Operations | NA | 0 | 0 | 0 | 0 |
Net Income (GAAP) | NA | -59 | -48 | -18 | -21 |
Depreciation Footnote | 3/31/24 | 3/31/23 | 3/31/22 | 3/31/21 | 3/31/20 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | 0 | -59 | -48 | -18 | -21 |
Depreciation & Amortization (Cash Flow) | NA | 0 | 0 | 0 | 0 |
Income After Depreciation & Amortization | 0 | -59 | -48 | -18 | -21 |
Earnings Per Share Data | 3/31/24 | 3/31/23 | 3/31/22 | 3/31/21 | 3/31/20 |
---|---|---|---|---|---|
Average Shares | NA | 6.96 | 6.59 | 2.87 | 1.46 |
Diluted EPS Before Non-Recurring Items | NA | -8.51 | -7.51 | -14.72 | -15.02 |
Diluted Net EPS (GAAP) | NA | -8.51 | -7.51 | -14.71 | -15.02 |
Fiscal Year end for VistaGen Therapeutics, Inc falls in the month of March .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | NA | 0.41 | 0.28 | 0.18 | 0.18 |
Cost Of Goods | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | NA | 0.41 | 0.28 | 0.18 | 0.18 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 8.30 | 7.06 | 7.18 | 12.42 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -7.89 | -6.78 | -7.00 | -12.24 |
Non-Operating Income | NA | 1.53 | 0.19 | 0.10 | 0.01 |
Interest Expense | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | NA | -6.35 | -6.59 | -6.90 | -12.23 |
Income Taxes | NA | 0.00 | 0.00 | 0.00 | -0.01 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -6.35 | -6.59 | -6.90 | -12.22 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -6.35 | -6.59 | -6.90 | -12.23 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | NA | 29.39 | 10.04 | 7.38 | NA |
Diluted EPS Before Non-Recurring Items | NA | -0.22 | -0.66 | -0.94 | NA |
Diluted Net EPS (GAAP) | NA | -0.22 | -0.66 | -0.94 | -1.60 |